Contact Us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Blood-based biomarker testing is reshaping how neurological diseases like Alzheimer’s are evaluated and managed, and labs are at the center of this change. This page brings together key resources to help you go deeper on the topics discussed and consider what neurology testing could look like in your institution.
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Gain an overview of Alzheimer’s disease, including its clinical impact, the need for earlier and more accurate diagnosis, and how evolving treatment options are changing diagnostic expectations.
Learn how cognitive assessments, imaging, CSF testing, and blood-based biomarkers work together across the Alzheimer’s disease diagnostic pathway, and where each tool can add value.
Discover practical ways to integrate neurology diagnostics into existing lab and clinical workflows, including key stakeholders to engage and implementation considerations.
Explore how innovations in blood-based biomarker tests may transform neurology diagnostics in the lab and support earlier, more informed clinical decisions.
If you would like more information on our pTau181 assay, share your details and a Roche representative will reach out shortly.